136 related articles for article (PubMed ID: 22741047)
1. Tumor establishment features of orthotopic murine bladder cancer models.
Lee JS; Bae MH; Choi SH; Lee SH; Cho YS; Park HJ; Kwon CH; Joo KJ
Korean J Urol; 2012 Jun; 53(6):396-400. PubMed ID: 22741047
[TBL] [Abstract][Full Text] [Related]
2. Optimizing orthotopic bladder tumor implantation in a syngeneic mouse model.
Chan ES; Patel AR; Smith AK; Klein JB; Thomas AA; Heston WD; Larchian WA
J Urol; 2009 Dec; 182(6):2926-31. PubMed ID: 19846165
[TBL] [Abstract][Full Text] [Related]
3. Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model.
Horiguchi Y; Larchian WA; Kaplinsky R; Fair WR; Heston WD
Gene Ther; 2000 May; 7(10):844-51. PubMed ID: 10845722
[TBL] [Abstract][Full Text] [Related]
4. Establishment of orthotopic mouse superficial bladder tumor model for studies on intravesical treatments.
Horiguchi Y; Kikuchi E; Ozu C; Nishiyama T; Oyama M; Horinaga M; Yoshioka K; Tachibana M
Hum Cell; 2008 Aug; 21(3):57-63. PubMed ID: 18667021
[TBL] [Abstract][Full Text] [Related]
5. [Establishment and application of an orthotopic murine bladder cancer model].
Yang SM; Wen DG; Hou JQ; He J; Cen JN; Chen JH
Ai Zheng; 2007 Apr; 26(4):341-5. PubMed ID: 17430648
[TBL] [Abstract][Full Text] [Related]
6. Histopathological characterization of a syngeneic orthotopic murine bladder cancer model.
Chade DC; Andrade PM; Borra RC; Leite KR; Andrade E; Villanova FE; Srougi M
Int Braz J Urol; 2008; 34(2):220-6; discussion 226-9. PubMed ID: 18462521
[TBL] [Abstract][Full Text] [Related]
7. Intravesical dual PI3K/mTOR complex 1/2 inhibitor NVP-BEZ235 therapy in an orthotopic bladder cancer model.
Matsushima M; Kikuchi E; Matsumoto K; Hattori S; Takeda T; Kosaka T; Miyajima A; Oya M
Int J Oncol; 2015 Jul; 47(1):377-83. PubMed ID: 25963317
[TBL] [Abstract][Full Text] [Related]
8. Intravesical interleukin-15 gene therapy in an orthotopic bladder cancer model.
Matsumoto K; Kikuchi E; Horinaga M; Takeda T; Miyajima A; Nakagawa K; Oya M
Hum Gene Ther; 2011 Nov; 22(11):1423-32. PubMed ID: 21554107
[TBL] [Abstract][Full Text] [Related]
9. The establishment of a growth-controllable orthotopic bladder cancer model through the down-regulation of c-myc expression.
Seo HK; Shin SP; Jung NR; Kwon WA; Jeong KC; Lee SJ
Oncotarget; 2017 Aug; 8(31):50500-50509. PubMed ID: 28881578
[TBL] [Abstract][Full Text] [Related]
10. An orthotopic xenograft model for high-risk non-muscle invasive bladder cancer in mice: influence of mouse strain, tumor cell count, dwell time and bladder pretreatment.
Huebner D; Rieger C; Bergmann R; Ullrich M; Meister S; Toma M; Wiedemuth R; Temme A; Novotny V; Wirth MP; Bachmann M; Pietzsch J; Fuessel S
BMC Cancer; 2017 Nov; 17(1):790. PubMed ID: 29169339
[TBL] [Abstract][Full Text] [Related]
11. [A simple and efficient method for establishing a mouse model of orthotopic MB49 bladder cancer].
Liang ZK; Zhang L; Hu ZM; Chen Z; Huang X; Shi XH; Tan WL; Gao JM
Nan Fang Yi Ke Da Xue Xue Bao; 2009 Apr; 29(4):627-30. PubMed ID: 19403380
[TBL] [Abstract][Full Text] [Related]
12. Nonviral cytokine gene therapy on an orthotopic bladder cancer model.
Wu Q; Mahendran R; Esuvaranathan K
Clin Cancer Res; 2003 Oct; 9(12):4522-8. PubMed ID: 14555526
[TBL] [Abstract][Full Text] [Related]
13. The anti-tumor effect of intravesical administration of normal urothelial cells on bladder cancer.
Huang CP; Chen CC; Shyr CR
Cytotherapy; 2017 Oct; 19(10):1233-1245. PubMed ID: 28818454
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the immunologic mechanism of intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors: distribution and function of immune cells.
Chung JY; Lee ES; Lee WJ; Kim HH; Min KJ; Lee C
J Korean Med Sci; 1993 Apr; 8(2):135-44. PubMed ID: 8397930
[TBL] [Abstract][Full Text] [Related]
15. Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model.
Horinaga M; Harsch KM; Fukuyama R; Heston W; Larchian W
Urology; 2005 Aug; 66(2):461-6. PubMed ID: 16040105
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of intravesical Bacillus Calmette-Guérin therapy against tumor immune escape in an orthotopic model of bladder cancer.
Huang P; Ma C; Xu P; Guo K; Xu A; Liu C
Exp Ther Med; 2015 Jan; 9(1):162-166. PubMed ID: 25452795
[TBL] [Abstract][Full Text] [Related]
17. Development of a murine intravesical orthotopic human bladder cancer (mio-hBC) model.
Raven PA; D'Costa NM; Moskalev I; Tan Z; Frees S; Chavez-Munoz C; So AI
Am J Clin Exp Urol; 2018; 6(6):245-259. PubMed ID: 30697580
[TBL] [Abstract][Full Text] [Related]
18. Effects of acetylic salicylic acid and pentoxifylline on the efficacy of intravesical BCG therapy in orthotopic murine bladder cancer (MB49).
Günther JH; Frambach M; Deinert I; Brandau S; Jocham D; Böhle A
J Urol; 1999 May; 161(5):1702-6. PubMed ID: 10210443
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall.
Olbert PJ; Schrader AJ; Simon C; Dalpke A; Barth P; Hofmann R; Hegele A
Anticancer Res; 2009 Jun; 29(6):2067-76. PubMed ID: 19528466
[TBL] [Abstract][Full Text] [Related]
20. Curcumin prevents intravesical tumor implantation of the MBT-2 tumor cell line in C3H mice.
Sindhwani P; Hampton JA; Baig MM; Keck R; Selman SH
J Urol; 2001 Oct; 166(4):1498-501. PubMed ID: 11547120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
